Similar articles for PMID: 10360125

Year	Number of Results
1956	1
1975	1
1977	1
1978	1
1984	1
1985	1
1986	2
1987	1
1988	6
1989	8
1990	6
1991	5
1992	5
1993	12
1994	5
1995	19
1996	13
1997	27
1998	33
1999	22
2000	30
2001	18
2002	19
2003	12
2004	18
2005	21
2006	13
2007	11
2008	12
2009	15
2010	11
2011	15
2012	16
2013	14
2014	8
2015	8
2016	16
2017	14
2018	16
2019	10
2020	10
2021	10
2022	6
2023	1
2024	0

1

Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L. Nyberg S, et al. Am J Psychiatry. 1999 Jun;156(6):869-75. doi: 10.1176/ajp.156.6.869. Am J Psychiatry. 1999. PMID: 10360125 Clinical Trial.

2

A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.

Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P. Kapur S, et al. Arch Gen Psychiatry. 2000 Jun;57(6):553-9. doi: 10.1001/archpsyc.57.6.553. Arch Gen Psychiatry. 2000. PMID: 10839333 Clinical Trial.

3

Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.

Kapur S, Zipursky RB, Remington G. Kapur S, et al. Am J Psychiatry. 1999 Feb;156(2):286-93. doi: 10.1176/ajp.156.2.286. Am J Psychiatry. 1999. PMID: 9989565

4

5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.

Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S. Kapur S, et al. Am J Psychiatry. 1998 Jul;155(7):921-8. doi: 10.1176/ajp.155.7.921. Am J Psychiatry. 1998. PMID: 9659858 Clinical Trial.

5

Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.

Graff-Guerrero A, Rajji TK, Mulsant BH, Nakajima S, Caravaggio F, Suzuki T, Uchida H, Gerretsen P, Mar W, Pollock BG, Mamo DC. Graff-Guerrero A, et al. JAMA Psychiatry. 2015 Sep;72(9):927-34. doi: 10.1001/jamapsychiatry.2015.0891. JAMA Psychiatry. 2015. PMID: 26131622

6

A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.

Remington G, Mamo D, Labelle A, Reiss J, Shammi C, Mannaert E, Mann S, Kapur S. Remington G, et al. Am J Psychiatry. 2006 Mar;163(3):396-401. doi: 10.1176/appi.ajp.163.3.396. Am J Psychiatry. 2006. PMID: 16513859 Free article.

7

Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.

Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S. Mamo D, et al. Am J Psychiatry. 2007 Sep;164(9):1411-7. doi: 10.1176/appi.ajp.2007.06091479. Am J Psychiatry. 2007. PMID: 17728427 Clinical Trial.

8

Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.

Dresel S, Tatsch K, Dähne I, Mager T, Scherer J, Hahn K. Dresel S, et al. J Nucl Med. 1998 Jul;39(7):1138-42. J Nucl Med. 1998. PMID: 9669383 Free article.

9

Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia.

Gefvert O, Bergström M, Långström B, Lundberg T, Lindström L, Yates R. Gefvert O, et al. Psychopharmacology (Berl). 1998 Jan;135(2):119-26. doi: 10.1007/s002130050492. Psychopharmacology (Berl). 1998. PMID: 9497016 Clinical Trial.

10

High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study.

Kapur S, Remington G, Jones C, Wilson A, DaSilva J, Houle S, Zipursky R. Kapur S, et al. Am J Psychiatry. 1996 Jul;153(7):948-50. doi: 10.1176/ajp.153.7.948. Am J Psychiatry. 1996. PMID: 8659621 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

450 results

Results by year